Navigation Links
Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Date:3/20/2017

Avexegen Therapeutics Inc., an innovative biotechnology company developing novel therapies for gastrointestinal (GI) disorders, today announced that it has entered into an exclusive global license agreement with Children’s Hospital Los Angeles (CHLA) for Neuregulin-4 (NRG-4) for therapies in inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s Disease and Ulcerative Colitis.

“With this licensing deal, Avexegen will continue to advance on its strategy to develop therapies for high unmet need GI disorders,” said Artin Asadourian, CEO of Avexegen Therapeutics.

Mark Frey, PhD, a principal investigator at The Saban Research Institute of CHLA, has demonstrated NRG-4 therapeutic proof of concept in preclinical models of NEC and inflammatory bowel disease. NRG-4’s efficacy is mediated by dual mechanisms that promote mucosal healing: the direct protection of the intestinal barrier and the suppression of inflammatory cytokines via its novel immunomodulatory action.

Currently, there are no FDA approved drugs for the treatment or prevention of Necrotizing Enterocolitis (NEC), which is a life-threatening disease that afflicts very low birth weight premature infants. NRG-4 has the potential to be the first such therapy for NEC.

About Avexegen Therapeutics, Inc.
Avexegen, founded in December 2014, is an emerging privately held biotech company based in San Diego, CA focused on developing novel treatments for a broad spectrum of inflammatory GI disorders. For more information please visit http://www.avexegen.com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14155590.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
2. eFFECTOR Therapeutics Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
3. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
4. Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017
5. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
6. Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting
7. Stealth BioTherapeutics Initiates Observational Study of Patients With Mitochondrial Myopathy
8. Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
10. Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
11. Capricor Therapeutics to Present at Two Investor Conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... ... spoke at a Marketing Roundtable on March 22 in Philadelphia. The event was ... , The Marketing Roundtable featured breakout groups and interaction with ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017  (AACR17, ... single-cell sequencing during the American Association for Cancer Research ... Center in Washington, D.C. , April ... gene expression of thousands of cells at the individual ... Experts on-hand at AACR to discuss expanded ...
(Date:3/28/2017)... , March 28, 2017 Dr. ... life sciences corporation Anpac Bio-Medical Science Company ... new, international record, processing and reporting over 40,000 ... Differentiation Analysis" (CDA) liquid biopsy tests. ... Prize Laureate Summit publications, Anpac Bio,s CDA medical ...
(Date:3/28/2017)... Focus is on the ... to the scientifically intensive operations of companies in ... and industrial. In today,s pre-market research, Stock-Callers.com dedicates attention ... PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera Therapeutics Inc. ... OCUL ). Learn more about these stocks ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
Breaking Biology News(10 mins):